Subscribe to our Email Alerts
Neuren Pharmaceuticals
  • Home
  • About Us
    • Company Overview
    • Company Values
    • Board of Directors
    • Management
    • Corporate Directory
  • Products
    • DAYBUE™ (trofinetide)
  • Pipeline
    • Pipeline
    • Trofinetide
      • Rett Syndrome
      • Fragile X Syndrome
    • NNZ-2591
      • Phelan-McDermid Syndrome
      • Angleman Syndrome
      • Pitt Hopkins Syndrome
      • Prader-Willi Syndrome
  • Science
    • Science Behind Neuren's Products
    • Scientific Presentations
    • Publications
  • Investors
    • Investor Dashboard
    • Share Price Information
    • ASX Announcements
    • Annual and Interim Reports
    • Investor Presentations
    • Corporate Governance
    • Analyst Coverage
    • Shareholder Services
  • News & Media
    • Media
  • Contact
    • Contact Us
    • Email Alerts

Investors

 

Home > Investors > Investor Presentations
  • Investor Dashboard
  • Share Price Information
  • ASX Announcements
  • Annual and Interim Reports
  • Investor Presentations
  • Corporate Governance
  • Analyst Coverage
  • Shareholder Services

Investor Presentations


 
17-Mar-2023    Investor webinar, 14 March 2023  
 
14-Mar-2023    Investor Presentation, 14 March 2023  
 
12-Jan-2023    Acadia presentation - 41st Annual J.P. Morgan Healthcare Conference  
 
7-Dec-2022    MST Financial: Late Stage Biotech Forum, 30 Nov 2022  
 
29-Nov-2022    Bell Potter Healthcare Conference, 8 Nov 2022  
 
30-May-2022    AGM Chairman's Address & CEO Presentation  
 
25-Feb-2022    Investor webinar, 25 February 2022  
 
29-Jun-2021    MST Access Australian Micro & Small Caps Conference 2021 15 June 2021  
 

Quick Links

Contact Us

Neuren Pharmaceuticals Limited
Suite 201, 697 Burke Road
Camberwell, VIC 3124
Australia

Phone: +61 (3) 9092 0480
Email: enquiries@neurenpharma.com

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Neuren Pharmaceuticals
Site Map Privacy Search
Site by